By The Life Science Report
Source: Streetwise Reports 03/06/2019
By tucking in this retinal gene therapy firm, the Massachusetts-based company gains assets and synergy.
In a March 4 BTIG research note, analyst Thomas Shrader reported that Biogen Inc. (BIIB:NASDAQ) entered into an agreement to acquire Nightstar Therapeutics Plc (NITE:NASDAQ) for about $800 million, or $25.50 in cash per Nightstar share. Biogen expects the acquisition will close by mid-2019.
Shrader outlined what Nightstar, a retinal gene therapy developer, offers Biogen. Nightstar has two late-stage assets for ophthalmologic indications that “represent risk-mitigated opportunities for gene therapy and mesh well with Biogen’s central nervous system expertise,” he indicated.
Get our Weekly Commitment of Traders Report: - See where the biggest traders (Hedge Funds and Commercial Hedgers) are positioned in the futures markets on a weekly basis.
Get Our Free Metatrader 4 Indicators - Put Our Free MetaTrader 4 Custom Indicators on your charts when you join our Weekly Newsletter
Nightstar’s lead asset, NSR-REP1, is an adeno-associated virus (AAV)-based gene therapy being developed for choroideremia, a condition characterized by progressive vision loss. Phase 3 data are expected for the therapeutic in this indication in H2/20. The other therapy, NSR-RPGR, is being developed for X-linked retinitis pigmentosa; a Phase 2/3 study in this indication is in the enrollment phase.
As for the market potential of the drug candidates, these two conditions afflict about 15,000 and 20,000 people, respectively, in the Group of Seven alone, highlighted Shrader.
The early-stage assets in Nightstar’s pipeline “also look good,” and “have the potential to be further sources of upside in the future,” Shrader pointed out. They include preclinical AAV-based product candidates for Stargardt disease, Best disease and additional retinitis pigmentosa programs.
Shrader noted that Biogen’s next acquisition might be related to the indication of Huntington’s disease, which “would make a lot of sense.”
BTIG has a Buy rating and a $362 per share 12-month target price on Biogen, whose stock is currently trading at around $326.87 per share.
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
Disclosures from BTIG, Biogen Inc., Equity Research, March 4, 2019
Analyst Certification I, Thomas Shrader, PhD, CFA, hereby certify that the views about the companies and securities discussed in this report are accurately expressed and that I have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report.
I, Julian Harrison, hereby certify that the views about the companies and securities discussed in this report are accurately expressed and that I have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report.
The research analyst(s) responsible for the preparation of this report receives compensation based upon a variety of factors, including the quality and accuracy of research, internal/client feedback, and overall Firm revenues.
( Companies Mentioned: BIIB:NASDAQ,